PFE - 3 Reasons Pfizer's Imminent Upjohn-Mylan Merger Is Great News for Investors
Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more.
A long-awaited deal will soon be done. Pfizer (NYSE: PFE) and Mylan (NASDAQ: MYL) announced last week that the U.S. Federal Trade Commission has approved the planned merger of Pfizer's Upjohn unit with Mylan to form a new entity, Viatris. Pfizer's spinoff of Upjohn will happen at the close of business on Nov. 13, 2020, with the merger of Upjohn and Mylan closing three days later .
How will current Pfizer shareholders be impacted? It's positive from nearly every angle. Here are three reasons why the imminent Upjohn-Mylan merger is great news for investors.
For further details see:
3 Reasons Pfizer's Imminent Upjohn-Mylan Merger Is Great News for Investors